Sean Wharton, MD, PharmD, discusses new data on survodutide from the phase 3 SYNCHRONIZE-2 trial.
Sean Wharton, MD, PharmD
Advertisement
Sean Wharton, MD, PharmD, is the director of Wharton Medical Clinic.
Articles by Sean Wharton, MD, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
2
FDA Accepts Inhaled Treprostinil sNDA for IPF: 4 FAQs for Payers
3
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
4
Proposed Medicare Rate Cuts Draw AASM Opposition Ahead of Final Rule
5